Download Bayesian designs for phase I-II clinical trials by Ying Yuan, Hoang Q. Nguyen, Peter F. Thall PDF

By Ying Yuan, Hoang Q. Nguyen, Peter F. Thall

Reliably optimizing a brand new remedy in people is a serious first step in medical assessment seeing that settling on a suboptimal dose or time table could lead to failure in later trials. whilst, if promising preclinical effects don't translate right into a genuine therapy improve, it is very important be certain this speedy and terminate the medical assessment technique to save some assets.

Bayesian Designs for part I–II scientific Trials describes how part I–II designs can function a bridge or protecting barrier among preclinical reviews and big confirmatory medical trials. It illustrates the various serious drawbacks with traditional tools used for early-phase medical trials and provides a variety of Bayesian designs for human scientific trials of latest experimental remedy regimes.

The first chapters reduce the technical language to cause them to available to non-statisticians. those chapters speak about the critical drawbacks of the normal paradigm used for early-phase scientific trials and clarify the part I–II paradigm for optimizing dose, or extra normal remedy regimes, in keeping with either efficacy and toxicity. the rest of the booklet covers a large choice of medical trial methodologies, together with designs to optimize the dose pair of a two-drug mix, together optimize dose and agenda, establish optimum customized doses, optimize novel molecularly unique brokers, and select doses in therapy cycles.

Written via learn leaders from the collage of Texas MD Anderson melanoma middle, this publication exhibits how Bayesian designs for early-phase medical trials can discover, refine, and optimize new experimental remedies. It emphasizes the significance of basing judgements on either efficacy and toxicity.

Show description

Read or Download Bayesian designs for phase I-II clinical trials PDF

Best biostatistics books

Neurological disorders. Public health challenges

There's considerable proof that pinpoints neurological issues as one of many maximum threats to public healthiness. There are numerous gaps in realizing the various concerns on the topic of neurological problems, yet we already understand adequate approximately their nature and therapy on the way to form potent coverage responses to a couple of the main normal between them.

Fundamentals of Biostatistics 5th Edition (without Data Disk)

Bernard Rosner's basics OF BIOSTATISTICS is a realistic advent to the equipment, suggestions, and computation of facts with human matters. It prepares scholars for his or her destiny classes and careers by way of introducing the statistical tools ordinarily utilized in clinical literature. Rosner minimizes the quantity of mathematical formula (algebra-based) whereas nonetheless giving entire motives of the entire vital recommendations.

New Developments in Biostatistics and Bioinformatics (Frontiers of Statistics)

This ebook offers an outline of contemporary advancements in biostatistics and bioinformatics. Written via lively researchers in those rising components, it truly is meant to provide graduate scholars and new researchers an concept of the place the frontiers of biostatistics and bioinformatics are in addition to a discussion board to profit universal ideas in use, which will boost the fields through constructing new concepts and new effects.

Scientific Papers and Presentations

Digital publishing and digital technique of textual content and information presentation have replaced tremendously because the first version of this ebook used to be released in 1997. The third variation of clinical Papers and Presentations applies conventional rules to trendy smooth suggestions and the altering wishes of up-and-coming academia.

Additional resources for Bayesian designs for phase I-II clinical trials

Example text

6 Expansion Cohorts The idea of adding so-called “expansion cohorts” to phase I trials began innocently enough, since it is based on what seems to be common sense. The idea is to first conduct a usual phase I trial to determine an MTD using the 3+3 algorithm or some other method, such as the CRM. Then, to obtain a better estimator of Pr(T oxicity | MTD), a small number of additional patients are treated at the MTD. When this practice was begun, typical expansion cohorts sizes were 3 to 10 patients.

The rationale, as explained in Chapter 1, is that πE (dj ) also increases in dj . Phase I–II dose-finding designs assume explicit models for both πT (dj ) and πE (dj ), and they seek a dose that has both acceptably low πT (dj ) and acceptably high πE (dj ). Since some doses may be either too toxic or unacceptably inefficacious, randomizing patients among the doses is not ethical. This motivates the use of sequentially adaptive designs. Each design assumes a Bayesian probability model consisting of a distri˜ bution p(Y |ρ, θ) of Y for a patient who receives regime ρ, and a prior p(θ|θ), where θ is the model parameter vector and θ˜ is a vector of fixed hyperparameters.

6 Expansion Cohorts The idea of adding so-called “expansion cohorts” to phase I trials began innocently enough, since it is based on what seems to be common sense. The idea is to first conduct a usual phase I trial to determine an MTD using the 3+3 algorithm or some other method, such as the CRM. Then, to obtain a better estimator of Pr(T oxicity | MTD), a small number of additional patients are treated at the MTD. When this practice was begun, typical expansion cohorts sizes were 3 to 10 patients.

Download PDF sample

Rated 4.95 of 5 – based on 24 votes